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Iron regulatory proteins 1 and 2 (IRP1 and IRP2) post-transcriptionally control the
expression of several mRNAs encoding proteins of iron, oxygen and energy metabolism.
The mechanism involves their binding to iron responsive elements (IREs) in the
untranslated regions of target mRNAs, thereby controlling mRNA translation or stability.
Whereas IRP2 functions solely as an RNA-binding protein, IRP1 operates as either
an RNA-binding protein or a cytosolic aconitase. Early experiments in cultured cells
established a crucial role of IRPs in regulation of cellular iron metabolism. More recently,
studies in mouse models with global or localized Irp1 and/or Irp2 deficiencies uncovered
new physiological functions of IRPs in the context of systemic iron homeostasis. Thus,
IRP1 emerged as a key regulator of erythropoiesis and iron absorption by controlling
hypoxia inducible factor 2α (HIF2α) mRNA translation, while IRP2 appears to dominate the
control of iron uptake and heme biosynthesis in erythroid progenitor cells by regulating the
expression of transferrin receptor 1 (TfR1) and 5-aminolevulinic acid synthase 2 (ALAS2)
mRNAs, respectively. Targeted disruption of either Irp1 or Irp2 in mice is associated
with distinct phenotypic abnormalities. Thus, Irp1−/− mice develop polycythemia and
pulmonary hypertension, while Irp2−/− mice present with microcytic anemia, iron overload
in the intestine and the liver, and neurologic defects. Combined disruption of both Irp1
and Irp2 is incombatible with life and leads to early embryonic lethality. Mice with
intestinal- or liver-specific disruption of both Irps are viable at birth but die later on due
to malabsorption or liver failure, respectively. Adult mice lacking both Irps in the intestine
exhibit a profound defect in dietary iron absorption due to a “mucosal block” that is caused
by the de-repression of ferritin mRNA translation. Herein, we discuss the physiological
function of the IRE/IRP regulatory system.
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PRINCIPLES OF MAMMALIAN IRON METABOLISM
Iron is a vital micronutrient and constituent of several metallo-
proteins (Aisen et al., 2001). Even though it may acquire many
oxidation states (from −2 to +6), within cells iron commonly
alternates between the ferrous Fe(II) and ferric Fe(III) forms.
Because of its abilities to coordinate with proteins and to act as
both an electron donor and an electron acceptor, iron has been
utilized throughout evolution by almost all living cells and organ-
isms for metabolic purposes. Thus, iron is an integral component
in: oxygen transport, through the heme moiety of hemoglobin;
cellular respiration, as part of heme-containing cytochromes and
Fe-S cluster-containing proteins of the electron transport chain
(ETC); DNA synthesis and cellular growth, as part of the M2
subunit of ribonucleotide reductase.
As essential as iron is to survival, it can also be toxic. “Free”
iron engages in Fenton chemistry to catalyze the production
of hydroxyl radicals from superoxide and hydrogen peroxide
(Papanikolaou and Pantopoulos, 2005). These are extremely reac-
tive species that can damage lipid membranes, proteins and
nucleic acids within a cell. To avoid the deleterious effects
of the Fenton reaction, iron has to be shielded. Circulating
iron is oxidized to Fe(III) and tightly binds to transferrin
(Tf), which maintains it in a redox-inert state and delivers
it to tissues (Gkouvatsos et al., 2012). Cellular iron uptake
involves the binding of iron-loaded Tf to transferrin receptor
1 (TfR1) and the internalization of the complex by endocyto-
sis (Aisen, 2004). Within endosomes, Fe(III) is released from
Tf following acidification, and undergoes reduction to Fe(II).
Subsequently, Fe(II) crosses the endosomal membrane via the
divalent metal transporter 1 (DMT1). Internalized iron is mostly
utilized in mitochondria for synthesis of heme and Fe-S clus-
ters, and in the cytosol for incorporation into metalloproteins,
while excess of iron is stored and detoxified within ferritin
(Arosio et al., 2009). Ferritin is ubiquitously expressed in the
cytosol of cells. It is comprised of 24 H- and L-polypeptide
subunits that form a shell-like nanocage for iron storage, with
a diameter of 7–8 nm. This can accommodate up to 4500
iron atoms, which are safely stored in the form of ferric oxy-
hydroxide phosphate, following oxidation of Fe(II) to Fe(III)
at the ferroxidase center of the H-ferritin subunit. In addition,
a distinct ferritin isoform (M-ferritin) is expressed in mito-
chondria of some cell types, such as testicular Leydig cells,
neuronal cells and pancreatic islets of Langherans (Levi and
Arosio, 2004).
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The iron content of the adult human body ranges between 3
and 5 g (Gkouvatsos et al., 2012). Most of it (∼70%) is utilized
in hemoglobin of red blood cells (RBCs) in the bloodstream and
of erythroid progenitor cells in the bone marrow, and is recy-
cled by tissue macrophages at a rate of 25–30mg/day (Figure 1).
A substantial amount of body iron (up to 1 g) is stored within
ferritin in the liver. Muscles contain ∼300mg of iron (mostly
in myoglobin), and all other tissues (excluding the duodenum)
merely ∼8mg. Circulating Tf-bound iron represents a small
(∼3mg) but dynamic fraction that turns over ∼10 times per day
(Cavill, 2002). The Tf iron pool is primarily replenished by iron
from senescent RBCs that is recycled via macrophages, and to a
smaller extent by iron absorbed from the diet via duodenal ente-
rocytes. In adults, dietary iron absorption (1–2mg/day) serves
to compensate for non-specific iron losses (by desquamation or
bleeding).
Iron metabolism is regulated at both the systemic and cellu-
lar levels. Systemic iron homeostasis is controlled through hep-
cidin, a liver-derived peptide hormone (Ganz, 2013). Iron and
other stimuli (inflammation, endoplasmic reticulum stress) pos-
itively regulate hepcidin transcription, while erythropoietic drive
suppresses it. Hepcidin binds to the cellular iron exporter ferro-
portin expressed on enterocytes, macrophages, and hepatocytes
causing ferroportin’s subsequent internalization and degrada-
tion (Nemeth et al., 2004). Ergo hepcidin functions to con-
trol iron absorption within the enterocytes and the efflux of
iron into the bloodstream from macrophages and other iron
exporting cells (Figure 2). Misregulation of hepcidin is associ-
ated with disease (hemochromatosis, when iron-regulation of
hepcidin is blunted, and anemia, when hepcidin is induced by
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FIGURE 1 | Distribution and dynamics of iron traffic in the human
body.
inflammatory pathways or by genetic inactivation of its inhibitor
TMPRSS6) (Sebastiani and Pantopoulos, 2011). Cellular iron
metabolism is controlled through the IRE/IRP system (Wang and
Pantopoulos, 2011; Joshi et al., 2012), which is the focus of this
review.
COORDINATE POST-TRANSCRIPTIONAL REGULATION OF
CELLULAR IRON METABOLISM VIA IRE/IRP INTERACTIONS
The IRE/IRP regulatory system was first described in the late
1980s with the discovery of iron responsive elements (IREs) in
the untranslated regions (UTRs) of the mRNAs encoding fer-
ritin (both H- and L-subunits) and TfR1 (Hentze et al., 1987;
Casey et al., 1988; Müllner and Kühn, 1988); see Figure 3. IREs
are highly conserved hairpin structures of 25–30 nucleotides
(Piccinelli and Samuelsson, 2007). They contain a stem that is
stabilized by base pairing, and a loop with the sequence 5′-
CAGUGH-3′ (H denotes A, C or U). The stem is interrupted to
an upper and lower part by an unpaired C residue or an asym-
metric UGC/C bulge/loop. H- and L-ferritin mRNAs contain a
single IRE in their 5′ UTR, which is located relatively close to the
cap structure at the 5′ end. TfR1 mRNA contains five IREs in its
3′ UTR.
The IREs constitute binding sites of two cytoplasmic iron regu-
latory proteins, IRP1 and IRP2 (Rouault, 2006). Under conditions
of iron deficiency, IRP1 and IRP2 bind with high affinity to the
IRE in H- and L-ferritin mRNAs, and thereby inhibit their trans-
lation by a steric hindrance mechanism. Likewise, they bind to
the IREs in TfR1mRNA and thereby protect it against endonucle-
olytic degradation. This homeostatic response mediates increased
cellular iron uptake from Tf and prevents storage of the metal.
By contrast, in iron-replete cells the IRE-binding activities of
IRP1 and IRP2 are diminished, allowing TfR1mRNAdegradation
and ferritin mRNA translation. This inhibits further iron uptake
and stimulates storage of excessive intracellular iron within fer-
ritin. A scheme with the coordinate post-transcriptional regu-
lation of ferritin and TfR1 by IRE/IRP interactions is shown in
Figure 4.
Additional IRE-containing mRNAs (Figure 5) have been dis-
covered by computational and biochemical approaches, as well as
high throughput screens (Dandekar and Hentze, 1995; Gunshin
et al., 1997; McKie et al., 2000; Sanchez et al., 2006, 2007, 2011).
These include the mRNAs encoding the iron transporters DMT1
and ferroportin, the enzyme 5-aminolevulinic acid synthase 2
(ALAS2) that catalyzes the first reaction for heme biosynthe-
sis in erythroid progenitor cells, the enzyme of the citric acid
cycle mitochondrial aconitase, the cell cycle regulator CDC14A,
and hypoxia inducible factor 2 alpha (HIF2α), a transcrip-
tion factor that orchestrates molecular responses to hypoxia.
All these transcripts harbor a single IRE. The IRE of ferro-
portin, ALAS2, mitochondrial aconitase and HIF2α mRNAs is
localized in the 5′ UTR and functions as a translational con-
trol element, analogous to ferritin IRE. The IRE of DMT1 and
CDC14A mRNAs is localized in the 3′ UTR and appears to
function as an mRNA stability element. Post-transcriptional reg-
ulation of DMT1 expression by the IRE/IRP system is cell-specific
(Gunshin et al., 2001) and depends, at least partially, on an alter-
natively transcribed upstream exon at the 5′ end of DMT1mRNA
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FIGURE 2 | Hormonal regulation of iron efflux from reticuloendothelial
macrophages and duodenal enterocytes. The iron regulatory hormone
hepcidin is secreted by liver hepatocytes and targets the iron transporter
ferroportin on the plasma membrane of iron-exporting cells. The binding of
hepcidin promotes ferroportin degradation in lysosomes. Hepcidin expression
is induced in response to high iron stores and inflammatory signals.
Conversely, hepcidin expression is suppressed in response to iron deficiency
and increased erythropoietic drive.
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FIGURE 3 | IRE motifs in the untranslated regions of the mRNAs
encoding human H-ferritin, L-ferritin and TfR1 (only the A IRE of TfR1
mRNA is shown). Watson-Crick base pairing is depicted by a dash and
non-Watson-Crick interactions by a dot. The line connecting the 1st and 5th
nucleotide of the IRE loop indicates Watson-Crick base pairing.
(Hubert and Hentze, 2002). Notably, earlier experiments showed
that the presence of at least three 3′ UTR IREs is essential for
iron-dependent regulation of TfR1 mRNA (Casey et al., 1989),
which remains the only transcript containing multiple IREs.
It should also be noted that DMT1, ferroportin and CDC14A
mRNAs include additional non-IRE-containing isoforms, which
are generated by alternative splicing and exhibit differential tissue
distribution (Hubert and Hentze, 2002; Sanchez et al., 2006;
Zhang et al., 2009).
Another level of complexity is added by the fact that iron
regulation of HIF2α, ferroportin and DMT1 integrates multi-
ple and often opposing signals (Mastrogiannaki et al., 2013;
Shah and Xie, 2014). Thus, while iron stimulates HIF2α and fer-
roportin mRNA translation, it also promotes the degradation
of HIF2α via iron- and oxygen-dependent prolyl hydroxylases
(PHDs) and the von Hippel Lindau E3 ubiquitin ligase (pVHL)
(Schofield and Ratcliffe, 2004), and the degradation of ferroportin
via hepcidin (Ganz, 2013). Conversely, iron deficiency inhibits
translation of HIF2α and ferroportin mRNAs but promotes stabi-
lization of the proteins. On the other hand, iron deficiency leads
to HIF2α-mediated transcriptional activation of duodenal DMT1
and ferroportin, the apical and basolateral transporters of iron in
enterocytes (see below).
SENSING OF INTRACELLULAR IRON BY IRP1 AND IRP2
IRP1 and IRP2 are homologous to mitochondrial aconitase
(Rouault, 2006; Wang and Pantopoulos, 2011). A characteris-
tic feature of this enzyme is the presence of a 4Fe-4S cluster
within its active site, which is indispensable for catalytic isomer-
ization of citrate to iso-citrate. IRP1 assembles an aconitase-type
4Fe-4S cluster in response to increased intracellular iron lev-
els. The complex pathway involves several co-factors, such as
Nfs1 (ISCS), frataxin, ISCU, glutaredoxin 5 (GLRX5) and oth-
ers. Assembly of the 4Fe-4S cluster alters the conformation of
IRP1 and precludes IRE-binding (Dupuy et al., 2006; Walden
et al., 2006). At the same time holo-IRP1 (containing the 4Fe-4S
cluster) acquires enzymatic activity as cytosolic aconitase, which
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FIGURE 4 | Coordinate iron-dependent regulation of ferritin and TfR1
mRNA expression by IRE/IRP interactions. Iron deficiency promotes the
binding of IRPs to cognate IREs in the untranslated regions of ferritin and
TfR1 mRNAs. These inhibit ferritin mRNA translation and stabilize TfR1
mRNA against endonucleolytic degradation. In iron-replete cells, IRPs do not
bind to IREs, allowing ferritin mRNA translation and TfR1 mRNA degradation.
is comparable to that of its mitochondrial counterpart. Iron
starvation, as well as other signals, such as nitric oxide (NO)
or hydrogen peroxide (H2O2), promotes the loss of the 4Fe-4S
cluster and conversion of apo-IRP1 to an IRE-binding pro-
tein (Haile et al., 1992; Drapier et al., 1993; Weiss et al., 1993;
Pantopoulos and Hentze, 1995). Thus, IRP1 is a bifunctional
protein that is regulated by an unusual 4Fe-4S cluster switch.
Holo-IRP1 is stabilized by hypoxia and at oxygen concentra-
tions ranging between 3 and 6%, which reflect physiological
tissue oxygenation (Meyron-Holtz et al., 2004b). Consistently
with this notion, IRP1 predominates in the cytosolic aconi-
tase form within tissues, but a fraction of apo-IRP1 is readily
detectable by virtue of its IRE-binding activity (Meyron-Holtz
et al., 2004a).
Contrary to IRP1, IRP2 does not bind an iron-sulfur cluster
and is regulated at the level of protein stability. IRP2 accumulates
in iron-starved and/or hypoxic cells, and undergoes proteaso-
mal degradation in iron-replete oxygenated cells. Mechanistically,
this involves ubiquitination of IRP2 by an E3 ubiquitin ligase
complex consisting of the F-box protein FBXL5 and the auxil-
iary proteins SKP1, CUL1, and RBX1 (Salahudeen et al., 2009;
Vashisht et al., 2009). FBXL5 exhibits genuine iron-sensing prop-
erties, as it is stabilized in the presence of iron and oxygen by
forming a Fe-O-Fe center within its N-terminal hemerythrin-
like domain. Loss of this center in iron-starved and/or hypoxic
cells exposes a degron via a conformational change (Chollangi
et al., 2012; Thompson et al., 2012). This allows proteasomal
degradation of FBXL5, which leads to concomitant accumulation
of IRP2. Interestingly, FBXL5 can also promote the ubiquiti-
nation and degradation of IRP1 mutants that cannot form a
4Fe-4S cluster (Salahudeen et al., 2009; Vashisht et al., 2009).
Proteasomal degradation of wild type apo-IRP1 under conditions
of impairment of the iron-sulfur cluster assembly pathway has
been proposed to operate as a reserve mechanism to control the
IRE-binding activity of IRP1 (Clarke et al., 2006; Wang et al.,
2007).
HUMAN DISEASES LINKED TO THE IRE/IRP SYSTEM
Mutations in the IRE of L-ferritin mRNA that abro-
gate IRP binding are causatively linked to the hereditary
hyperferritinemia-cataract syndrome (HHCS) (Beaumont et al.,
1995). The hallmark of this disorder is overexpression of serum
ferritin (up to 20-fold) in the absence of systemic iron overload
or inflammation (Yin et al., 2014). Patients also have an increased
tendency to develop bilateral cataract, which is possibly caused
by accumulation of non-functional L-ferritin homopolymers
in the lens (Levi et al., 1998). HHCS is transmitted in an auto-
somal dominant manner. Several HHCS-associated mutations
in L-ferritin IRE have been described (Luscieti et al., 2013).
Mutations affecting the loop structure or the C bulge result in
the highest levels of serum ferritin and increased severity of
cataract when compared with mutations in the stem structure of
the IRE (Cazzola et al., 1997). Overall, the severity of the clinical
phenotype appears to correlate with the degree of inhibition in
IRP binding (Allerson et al., 1999). Nevertheless, the involvement
of additional factors (genetic, environmental, inflammatory) has
not been excluded (Roetto et al., 2002).
A point mutation (A49U) in the loop of H-ferritin IRE has
been associated with an autosomal dominant iron overload dis-
order in a Japanese family (Kato et al., 2001). Iron deposits were
documented primarily in hepatocytes, but also in some Kupffer
cells. The A49U mutation increased the affinity of IRPs for H-
ferritin IRE and suppressed H-ferritin expression in cultured cells
(Kato et al., 2001). Nevertheless, it remains unclear how this
response promotes iron overload. The lack of follow-up studies
to support the validity of these findings should also be noted.
Disruption of the zebrafish glrx5 gene, encoding glutaredoxin
5, leads to constitutive activation of IRP1 for IRE-binding, due
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FIGURE 5 | IRE motifs in the untranslated regions of the mRNAs
encoding human ALAS2, CDC14A, mitochondrial aconitase, HIF2α,
ferroportin, and DMT1. Watson-Crick base pairing is depicted by a dash
and non-Watson-Crick interactions by a dot. The line connecting the 1st and
5th nucleotide of the IRE loop indicates Watson-Crick base pairing.
to defective assembly of its 4Fe-4S cluster (Wingert et al., 2005).
In a case report, a patient with GLRX5 deficiency developed
a sideroblastic-like anemia with microcytosis and systemic iron
overload (Camaschella et al., 2007). This disease is caused by
IRP1-mediated suppression of ALAS2 mRNA translation, which
results in impaired heme biosynthesis. A secondary effect is the
depletion of cytosolic iron and the development of mitochondrial
iron overload (Ye et al., 2010).
The above examples represent the only documented human
disorders that are causatively linked to defects in the IRE/IRP sys-
tem (Table 1). Genome-wide association studies (GWAS) showed
that the IRP2 gene (IREB2) confers susceptibility to chronic
obstructive pulmonary disease (COPD) (Demeo et al., 2009;
Chappell et al., 2011; Zhou et al., 2012) and lies within a lung
cancer-associated locus (Hansen et al., 2010; Cho et al., 2012;
Fehringer et al., 2012). Apart from the identification of sin-
gle nucleotide polymorphisms (SNPs) in IREB2, it was shown
that COPD patients exhibit increased IRP2 mRNA and protein
expression (Demeo et al., 2009) and it was speculated that this
may contribute to iron accumulation in the lungs. IREB2 poly-
morphisms have also been associated with Alzheimer’s disease
(Coon et al., 2006). Interestingly, biochemical studies showed
that IRP1 selectively regulates translation of amyloid precursor
protein (APP) mRNA by binding to an atypical putative IRE
motif (Cho et al., 2010), which may provide another connection
of the IRE/IRP system with Alzheimer’s disease. The IRP1 gene
(ACO1) has been associated with cutaneous malignant melanoma
(Yang et al., 2010) and neuropathic pain in HIV-infected patients
(Kallianpur et al., 2014), while the IRE-binding activity of IRP1
was reported to be increased in Friedreichs’ ataxia (Lobmayr et al.,
2005) and in Parkinson’s disease (Faucheux et al., 2002). Finally,
polymorphisms in bothACO1 and IREB2 have been linked to age-
related macular degeneration (Synowiec et al., 2012). GWAS data
with ACO1 and IREB2 are summarized in Table 2. The molecular
mechanisms by which IRPs may contribute to pathogenesis of the
above disorders remain to be established.
MOUSE MODELS WITH UBIQUITOUS ABERRATION IN THE
IRE/IRP SYSTEM
Mice with ubiquitous ablation of both Irp1 and Irp2 cannot
be generated because the embryos do not survive the blastocyst
stage, possibly due to misregulation of iron metabolism (Smith
et al., 2006). These data highlight the physiological significance
of the IRE/IRP system in early development. On the other hand,
single Irp1−/− or Irp2−/− mice are viable. At first glance, this
suggests that Irp1 and Irp2 share overlapping functions in vivo.
Nonetheless, Irp1−/− and Irp2−/− mice manifest distinct phe-
notypes, indicating variable target specificity. The phenotypic
features of current mouse models with global or tissue-specific
“loss” or “gain” of Irp1 and/or Irp2 functions are summarized in
Table 3.
Irp1−/− mice were initially reported to lack any overt abnor-
malities (Meyron-Holtz et al., 2004a; Galy et al., 2005a). Because
they merely misregulated ferritin and TfR1 expression in the
kidney and the brown fat, tissues with the highest abundance
of IRP1, it was proposed that Irp2 dominates cellular iron
metabolism in tissues, with Irp1 having an auxiliary physiologi-
cal function (Meyron-Holtz et al., 2004a). In addition, Irp1−/−
(and Irp2−/−) mice did not exhibit any defects when challenged
with turpentine to induce an inflammatory response (Viatte et al.,
2009), despite the fact that IRPs are modulated in cultured cells
by inflammatory reactive species such as H2O2 and NO (Weiss
et al., 1993; Pantopoulos and Hentze, 1995; Wang et al., 2005;
Hausmann et al., 2011).
Recently, Irp1−/− mice were documented to develop poly-
cythemia and pathological iron metabolism due to stress ery-
thropoiesis, as well as pulmonary hypertension and cardiac
hypertrophy and fibrosis (Anderson et al., 2013; Ghosh et al.,
2013; Wilkinson and Pantopoulos, 2013). These phenotypes are
attributed to relief of translational suppression of Hif2α mRNA,
which leads to transcriptional activation of the downstreamHif2α
targets erythropoietin and endothelin-1. Thus, murine Irp1 oper-
ates as specific regulator of the Hif2α IRE, in agreement with
previous in vitro data (Zimmer et al., 2008). Irp1−/− mice exhibit
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Table 1 | Human disorders that are causatively linked to defects in the IRE/IRP system.
Human disease Mutation Phenotype References
Hereditary
hyperferritinemia-cataract
syndrome (HHCS)
Mutations in the IRE of L-ferritin mRNA
that impair IRP binding
Overexpression of serum ferritin in the
absence of systemic iron overload or
inflammation. Tendency for the
development of bilateral cataract
(Beaumont et al., 1995; other
papers identified further
mutations)
Iron overload disorder
with autosomal dominant
transmission
Point mutation in the IRE loop of H-ferritin
that increases IRP binding
Suppression of H-ferritin leading to an iron
overload disorder phenotypically related to
hemochromatosis
Kato et al., 2001
Sideroblastic-like anemia
with iron overload
GLRX5 deficiency leading to increased
IRE-binding activity of IRP1 and
suppression of ALAS2 mRNA translation
Development of a sideroblastic-like
anemia with microcytosis and systemic
iron overload
Camaschella et al., 2007
Table 2 | Genome-wide association studies (GWAS) with the IRPI and IRP2 genes, ACO1 and IREB2, respectively.
Gene Disease Association References
IREB2 Chronic obstructive
pulmonary disease (COPD)
Patients with COPD have increased IRP2 mRNA and
protein expression in addition to a single nucleotide
polymorphism in IREB2
Demeo et al., 2009; Chappell et al.,
2011; Zhou et al., 2012
IREB2 Lung cancer Lies within a cancer-associated locus Hansen et al., 2010; Cho et al., 2012;
Fehringer et al., 2012
IREB2 Alzheimer’s disease IREB2 polymorphism have been associated with
Alzheimer’s disease
Coon et al., 2006
ACO1 Neuropathic pain in
HIV-infected patients
ACO1 was significantly associated with distal
neuropathic pain and pain severity in HIV-infected
patients on antiretroviral therapy
Kallianpur et al., 2014
ACO1 Cutaneous malignant
melanoma(CMM)
ACO1 was significantly associated with CMM and
training ability
Yang et al., 2010
ACO1 and
IREB2
Macular degeneration Polymorphisms in both ACO1 and IREB2 have been
linked to age related macular degeneration
Synowiec et al., 2012
high mortality when placed on an iron-deficient diet, which
is known to stabilize Hif2α, due to abdominal hemorrhages
(Ghosh et al., 2013). When Irp1−/− mice are fed with a stan-
dard diet, polycythemia attenuates after the 10th week of age
(Wilkinson and Pantopoulos, 2013), possibly due to enhanced
Hif2α degradation by the pVHL pathway. This may explain why
their pathology escaped attention in the past.
Irp2−/− mice develop microcytic hypochromic anemia and
erythropoietic protoporphyria, associated with relatively mild
duodenal and hepatic iron overload and splenic iron deficiency
(Cooperman et al., 2005; Galy et al., 2005b). They exhibit a low
Tfr1 content and express high levels of protoporphyrin IX in ery-
throid precursor cells. A closer look on the role of Irp1 and Irp2
in erythropoiesis, duodenal iron absorption and systemic iron
metabolism will be provided in the next sections.
Global Irp2−/− deficiency has also been associated with pro-
gressive neurodegeneration, loss of Purkinje neurons and iron
overload in white matter areas of the brain (LaVaute et al.,
2001; Ghosh et al., 2006), with more severe presentation in Irp1
haploinsufficient Irp1+/−Irp2−/− mice (Smith et al., 2004). The
neuronal pathology of Irp2−/− mice can be partially rescued by
pharmacological activation of endogenous Irp1 for IRE-binding
(Ghosh et al., 2008). Mechanistically, the pathology may be
caused by functional iron deficiency in neuronal cells due to de-
repression of ferritin mRNA translation, which could result in
enhanced iron storage and reduced availability for metabolic pur-
poses (Jeong et al., 2011). This scenario is reminiscent of neuro-
ferritinopathy, a neurodegenerative disease caused by expression
of mutant L-ferritin (Burn and Chinnery, 2006). Suppression of
Tfr1 and enhancement of ferroportin expression in Irp2−/− neu-
rons could also contribute to pathology. Nevertheless, isogenic
Irp2−/− mice generated by another strategy did not develop any
signs of neurodegeneration but rather manifested minor perfor-
mance deficits in specific neurological tests (motor coordination
and balance) (Galy et al., 2006). A third independent Irp2−/−
mouse strain was recently generated and analyzed, corroborating
the abnormalities in erythropoiesis and brain iron metabolism
of these animals; the latter were linked to mild neurological and
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Table 3 | Phenotypic features of mouse models with global or tissue-specific “loss” or “gain” of Irp1 and/or Irp2 functions.
Mouse model Site of
modification
Generation credit Phenotype Phenotype credit
Irp1−/− Global Meyron-Holtz et al., 2004a;
Galy et al., 2004
Polycythemia, stress erythropoiesis,
splenomegaly, and increased
expression of erythropoietin
Anderson et al., 2013;
Ghosh et al., 2013;
Wilkinson and
Pantopoulos, 2013
Pulmonary hypertension, cardiac
hypertrophy and cardiac fibrosis. Mice
succumb to hemorrhages when fed
an iron-deficient diet
Ghosh et al., 2013
Increased expression of Dmt1,
ferroportin and Dcytb mRNAs in the
duodenum
Anderson et al., 2013
Misregulation ferritin and Tfr1
expression in the kidney and brown fat
Meyron-Holtz et al.,
2004a
Efficient inflammatory signaling
response to turpentine
Viatte et al., 2009
Increased ferroportin expression on
splenic macrophages and decreased
hepcidin mRNA levels in the liver
Wilkinson and
Pantopoulos, 2013
Irp2−/− Global LaVaute et al., 2001; Galy et al.,
2004; Zumbrennen-Bullough
et al., 2014
Microcytic hypochromic anemia with
mild duodenal and hepatic iron
overload and splenic iron deficiency
Cooperman et al., 2005;
Galy et al., 2005b
Reduced TfR1 expression in erythroid
precursors
Cooperman et al., 2005;
Galy et al., 2005b
High levels of protoporphyrin IX in
erythroid precursors
Cooperman et al., 2005
Increased ferritin levels in all tissues Cooperman et al., 2005
Iron overload in neurons and
progressive neurodegeneration
LaVaute et al., 2001;
Ghosh et al., 2006
Efficient inflammatory signaling
response to turpentine
Viatte et al., 2009
Mild neurological and behavioral
defects, as well as nociception
Zumbrennen-Bullough
et al., 2014
Minor performance deficits in specific
neurological tests (motor coordination
and balance)
Galy et al., 2006
Irp2−/− Liver-specific Ferring-Appel et al., 2009 Mild hepatic iron overload Ferring-Appel et al., 2009
Irp2−/− Intestinal-
specific
Ferring-Appel et al., 2009 Mild duodenal iron overload Ferring-Appel et al., 2009
Irp2−/− Macrophage-
specific
Ferring-Appel et al., 2009 No pathology Ferring-Appel et al., 2009
Irp1−/−Irp2−/− Global Smith et al., 2006 Embryonic lethality at the blastocyst
stage of development
Smith et al., 2006
Irp1+/−Irp2−/− Global Smith et al., 2004 More serve presentation of neuronal
pathology than that of Irp2−/− mice
Smith et al., 2004
Neuronal pathology partially rescued
by the pharmacological activation of
endogenous Irp1
Ghosh et al., 2008
(Continued)
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Table 3 | Continued
Mouse model Site of
modification
Generation credit Phenotype Phenotype credit
Irp1−/−Irp2−/− Liver-specific Galy et al., 2010 Early lethality within 1–2 weeks after
birth due to liver failure
Galy et al., 2010
Irp1−/−Irp2−/− Intestinal-
specific
Galy et al., 2008 Growth retardation, early death
(within 30 days) due to dehydration.
Increased expression of ferritin,
ferroportin, and Dmt1
Galy et al., 2008
Irp1−/−Irp2−/− Adult
ligand-induced
intestinal-
specific
Galy et al., 2013 Increased expression of ferritin
leading to “mucosal block,” in spite of
increased expression of ferroportin
and Dmt1
Galy et al., 2013
Irp1 “gain of
function” due to
expression of a
constitutive IRP1
transgene
Global Casarrubea et al., 2013 Macrocytic erythropenia due to
impaired erythroid differentiation
Casarrubea et al., 2013
Irp2 “gain of
function” due to
disruption of Fbxl5
Global Moroishi et al., 2011; Ruiz et al.,
2013
Embryonic lethality Moroishi et al., 2011; Ruiz
et al., 2013
Irp2 “gain of
function” due to
disruption of Fbxl5
Liver-specific Moroishi et al., 2011 Hepatic iron overload and
steatohepatitis; low hepcidin mRNA
levels. Mice succumb to lethal liver
failure when fed a high-iron diet
Moroishi et al., 2011; Ruiz
et al., 2013
behavioral defects, as well as nociception (Zumbrennen-Bullough
et al., 2014). The discrepancies in the phenotypes of the three
Irp2−/− mouse lines may be related to the targeting strategies and
their impact on flanking genomic sequences, genetic factors, and
possibly also environmental factors.
Ubiquitous Irp1 “gain of function” mice were generated by
the transgenic expression of a constitutively active IRP1 mutant
from the Rosa26 locus (Casarrubea et al., 2013). Expression of
the transgene was relatively low and the mice developed erythro-
poietic abnormalities (macrocytic erythropenia due to impaired
erythroid differentiation).
The targeted disruption of Fbxl5 could yield ubiquitous Irp2
“gain of function” mice. Nevertheless, Fbxl5−/− mice are not
viable and die during embryogenesis (Moroishi et al., 2011; Ruiz
et al., 2013). This phenotype is rescued by concomitant disrup-
tion of Irp2, but not Irp1, indicating that the major physiological
function of Fbxl5 is to regulate Irp2.
THE IRE/IRP SYSTEM IN ERYTHROPOIESIS
Most iron in the body is utilized in erythropoiesis, a process that
occurs mainly in the bone marrow of humans and in the bone
marrow and spleen of mice (Cavill, 2002). Erythroid precursor
cells express high levels of TfR1 and consume the majority of
Tf-bound iron for the production of heme, the oxygen-binding
moiety of hemoglobin (Ponka, 1997). An adult human pro-
duces about 2 million RBCs per second. Increased erythropoi-
etic drive is known to stimulate iron absorption (Finch, 1994).
This is mediated by suppression of hepcidin expression, which
allows increased iron efflux to the bloodstream from duodenal
enterocytes and tissue macrophages (Ganz, 2013). During iron
deficiency, erythroid precursor cells will have priority for iron uti-
lization, for the production of RBCs, over cells in other tissues
(Finch, 1994). Maturation of erythroid cell is induced by erythro-
poeitin (EPO), a circulating glycoprotein hormone that prevents
apoptosis of erythroid progenitor cells (Koury and Bondurant,
1990). EPO is primarily synthesized in peritubular interstitial
fibroblasts of the kidney, and to a smaller extent in hepatocytes of
the liver. Murine Epo is transcriptionally activated during hypox-
emia by Hif2α (Rankin et al., 2007; Kapitsinou et al., 2010),
while Hif2α indirectly suppresses hepcidin expression by stim-
ulating erythropoiesis via Epo (Liu et al., 2012; Mastrogiannaki
et al., 2012). There are several points where the IRE/IRP system
regulates erythropoiesis.
First, the phenotype of Irp1−/− mice demonstrates that Irp1
operates as a key upstream regulator of Hif2α expression at the
level of mRNA translation (Anderson et al., 2013; Ghosh et al.,
2013; Wilkinson and Pantopoulos, 2013). Essentially, these ani-
mals exhibit features of Hif2α overexpression, which are also
manifested in patients with Chuvash polycythemia (Ang et al.,
2002), and other forms of familial polycythemia caused by “gain
of function” HIF2α mutations (Percy et al., 2008), or inactivat-
ing mutations in pVHL, a negative regulator of HIF2α stability
(Percy et al., 2006). One of them, is hyperproduction of Epo,
which causes splenomegaly due to extramedullary erythropoiesis,
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promotes expansion of late stage basophilic erythroblasts, as well
as polychromatic and orthochromatic erythroblasts, and finally
leads to reticulocytosis and polycythemia. Importantly, overex-
pression of hepatic Epo is rescued by intercrossing Irp1−/− and
liver-specific Hif2α−/−mice (Wilkinson and Pantopoulos, 2013).
On the other hand, the defects in erythroid differentiation docu-
mented in the constitutive IRP1 transgenic mice can be attributed
to reduced Hif2α expression (Casarrubea et al., 2013). Hence,
the translational regulation of HIF2α mRNA by IRP1 links iron
metabolism with erythropoiesis via EPO. Physiologically, this
response probably serves to contain EPO expression and sub-
sequent stimulation of erythropoiesis under conditions of iron
deficiency. In addition, it is tempting to speculate that stress acti-
vation of IRP1 (by H2O2 or NO) (Weiss et al., 1993; Pantopoulos
and Hentze, 1995) may contribute to the impairment of EPO pro-
duction that is frequently observed under chronic inflammatory
conditions or in chronic kidney disease (Weiss and Goodnough,
2005), via suppression of HIF2αmRNA translation.
The above data suggest that IRP1 functions as an iron and
oxygen sensor (Figure 6). According to this model, in normoxic
renal interstitial fibroblasts the small steady-state fraction of apo-
IRP1 inhibits HIF2α mRNA translation and thereby limits EPO
production to physiological levels. This fraction is expected to
increase in normoxic iron deficiency due to 4Fe-4S cluster dis-
assembly, further suppressing HIF2α and EPO expression as a
homeostatic response to reduced iron availability, consistently
with iron-restricted erythropoiesis. Conversely, increased iron
supply is expected to increase the abundance of holo-IRP1, allow-
ing de-repression of HIF2α mRNA translation. This response is
also favored by hypoxia, which is known to stabilize holo-IRP1.
Thus, in hypoxic and/or iron-replete renal interstitial fibroblasts,
unimpeded HIF2α mRNA translation leads to increased genera-
tion of EPO and thereby stimulates erythropoiesis, as a homeo-
static adaptation to the scarcity of oxygen and/or the abundance
of iron.
IRP2 is not involved in the regulation of HIF2αmRNA in vivo.
This makes physiological sense, since IRP2 is highly active under
hypoxia, whenHIF2α synthesis is required. Nevertheless, the phe-
notype of Irp2−/− mice suggests that IRP2 is a critical regulator
of other erythropoietic pathways. These animals present with
hypochromic microcytic anemia with reduced iron availability
for erythropoiesis (Cooperman et al., 2005; Galy et al., 2005b;
Zumbrennen-Bullough et al., 2014). This is not a result of global
iron deficiency but rather misregulation of cellular iron traffic.
Irp2−/− erythroid cells exhibit a reduced Tfr1 content, appar-
ently due to lack of Tfr1 mRNA stabilization in the absence of
Irp2. As a result, these cells fail to acquire sufficient amounts of
iron for erythropoiesis, in spite of the physiological iron supply,
which is reflected in the normal Tf saturation and total iron-
binding capacity (TIBC) in serum. Therefore, Irp2 appears to act
as major activator of Tfr1 in erythroid cells. It is conceivable that
this function is more pronounced at earlier stages of erythroid
development, considering that during terminal erythroid differ-
entiation, Tfr1 mRNA stability remains unresponsive to iron,
bypassing the IRE/IRP checkpoint (Schranzhofer et al., 2006).
Irp2−/− mice also manifest very high levels of free and
zinc protoporphyrin IX in RBCs (∼200-fold increase for free
protoporphyrin IX), consistently with erythropoietic protopor-
phyria (Cooperman et al., 2005). This is very likely caused by
enhanced heme biosynthetic activity due to de-repression of
Alas2 mRNA translation. In the absence of adequate iron, it
results in accumulation of free protoporphyrin IX and in incor-
poration of zinc in the protoporphyrin IX ring. Therefore, IRP2
also acts as a major regulator of ALAS2 mRNA translation via the
IRE in its 5′ UTR. The interpretation that IRP2 regulates ery-
throid iron uptake and utilization by controlling expression of
the IRE-containing TfR1 and ALAS2 mRNAs, respectively, is also
supported by data with tissue-specific Irp2−/− mice. Thus, liver-
or intestinal-specific ablation of Irp2 recapitulates the iron over-
load phenotype of these tissues in ubiquitous Irp2−/− mice, but
fails to promote microcytic anemia (Ferring-Appel et al., 2009).
THE IRE/IRP SYSTEM IN DIETARY IRON ABSORPTION
Dietary iron absorption takes place in brush border enterocytes
of the duodenum, especially in the upper tract. The pathway is
highly regulated at different levels. Hormonal regulation via hep-
cidin is well established. Hepcidin is produced in the liver in
response to high serum or hepatic iron (Corradini et al., 2011;
Ramos et al., 2011) and limits further iron absorption by promot-
ing the degradation of duodenal ferroportin (Nemeth et al., 2004;
Chung et al., 2009), the basolateral iron transporter. Hepcidin
may also promote degradation of DMT1, the apical iron trans-
porter, by the proteasome (Chung et al., 2009; Brasse-Lagnel
et al., 2011). Both ferroportin (Taylor et al., 2011) and DMT1
(Mastrogiannaki et al., 2009; Shah et al., 2009) are transcription-
ally activated in iron-deficient enterocytes by HIF2α. In addition,
ferroportin and DMT1 could be directly regulated by IRPs at the
levels of mRNA translation or stability, respectively. Duodenal
enterocytes also express ferritin, which limits excessive iron trans-
fer to the circulation (Vanoaica et al., 2010). TfR1 expression is
restricted to non-absorptive enterocytes in the intestinal crypts
(Waheed et al., 1999).
Iron deficiency elicits multiple and antagonistic signals on
duodenal ferroportin: transcriptional activation of its gene via
HIF2α (which is negatively regulated by IRP1), translational
repression of its mRNA via IRPs, and stabilization of the pro-
tein via downregulation of hepcidin. The net result is induction
of ferroportin, which is considered a physiologic response to
increase iron supply to the bloodstream (McKie et al., 2000). It
has been proposed that the IRP blockade can be bypassed via
enriched expression of an alternatively spliced non-IRE contain-
ing ferroportin transcript (Zhang et al., 2009). Nevertheless, in
other reports the canonical IRE-containing ferroportin mRNA
was found to be predominant in the duodenum of rats and mice
(Darshan et al., 2011; Galy et al., 2013). Another possibility is that
protein stabilization due to suppression of hepcidin is dominant.
Likewise, iron deficiency elicits multiple and antagonistic sig-
nals on duodenal DMT1: transcriptional activation of its gene
via HIF2α (which is negatively regulated by IRP1), possible sta-
bilization of its IRE-containing transcripts by IRPs, and possible
stabilization of the protein via downregulation of hepcidin. Again,
the net result is induction of DMT1 (Gunshin et al., 1997),
which serves to increase dietary iron absorption from the intesti-
nal lumen. Four different DMT1 mRNA isoforms are generated
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FIGURE 6 | Model for regulation of erythropoiesis by IRP1 via the
HIF2α/EPO axis. In iron-deficient or normoxic cells, apo-IRP1 limits
HIF2α synthesis by binding to HIF2α mRNA. Iron-replete conditions favor
conversion of apo- to holo-IRP1, at the expense of its IRE-binding
activity, allowing HIF2α mRNA translation and transcriptional activation of
its downstream target EPO. Hypoxia stabilizes holo-IRP1. Accumulation of
HIF2α is antagonized by the PHD/pVHL degradation system, which is
activated by oxygen and iron.
by the combination of alternative promoter usage and alter-
native splicing, and two of them harbor an IRE (Hubert and
Hentze, 2002). Interestingly, the IRE-containing DMT1 mRNAs
predominate in the duodenum and their expression is induced
in iron deficiency (Canonne-Hergaux et al., 1999; Hubert and
Hentze, 2002). Their transcription is selectively activated by
HIF2α (Mastrogiannaki et al., 2009; Shah et al., 2009).
Experiments with mice bearing global or enterocyte-specific
Irp deficiencies provided insights on the role of the IRE/IRP sys-
tem in dietary iron absorption. Irp1−/− mice express high levels
of duodenal ferroportin and IRE-Dmt1 mRNAs, most likely as a
result of de-repression of Hif2αmRNA translation and enhanced
Hif2α transcriptional activity in this tissue (Anderson et al.,
2013). This interpretation is consistent with the high expression
of further Hif2α target genes. Ferroportin and Dmt1 expression
was not altered in duodena of Irp2−/− mice, which exhibit iron
overload and express high levels of ferritin (Galy et al., 2005b).
High levels of duodenal ferritin were also documented in mice
with enterocyte-specific disruption of Irp2 (Ferring-Appel et al.,
2009). On the other hand, duodenal ferritin was not suppressed
in mice expressing the constitutive IRP1 transgene (Casarrubea
et al., 2013), in agreement with previous cell culture experiments
(Wang and Pantopoulos, 2002), possibly due to alternative fer-
ritin mRNA translation via internal initiation (Daba et al., 2012).
Thus, IRP2 alone appears to function as an important regulator
of ferritin but not ferroportin and DMT1 in the duodenum.
Mouse pups with enterocyte-specific deletion of both Irp1
and Irp2 are viable at birth but die within 4 weeks due to
malabsorption and dehydration, associated with abnormalities in
intestinal architecture (Galy et al., 2008). Their enterocytes man-
ifested highly increased expression of ferritin and ferroportin,
and reduced levels of Tfr1 and Dmt1. The downregulation of
ferritin and ferroportin was not associated with alterations in
their mRNA levels, reinforcing the role of IRPs in the regulation
of duodenal ferritin synthesis, but also demonstrating a promi-
nent function of the IRE/IRP system in translational control of
duodenal ferroportin mRNA. Expression of the major IRE-Dmt1
mRNA isoform was slightly reduced in the mutant mice, pro-
viding first in vivo evidence for a role of IRPs in the control of
IRE-DMT1 mRNA stability.
Adult mice with enterocyte-specific ablation of both Irp1 and
Irp2 were generated by using a tamoxifen-inducible Cre-deleter
strain under the control of the villin promoter (Galy et al.,
2013). These animals are viable and the ablation of Irps does not
significantly alter intestinal architecture. As expected, the expres-
sion of ferritin and ferroportin was very high, while Tfr1 levels
were low. Dmt1 was also upregulated, in contrast to the data
obtained in pups with enterocyte-specific deletion of both Irps
(Galy et al., 2008). The induction of Dmt1 was associated with
an increase in steady-state levels of the IRE-Dmt1 mRNA iso-
forms, which was attributed to transcriptional stimulation by
Hif2α. Together, the above data suggest that Irps regulate the IRE-
Dmt1 mRNA only in newborn mice but not in adult animals.
This is consistent with the notion that duodenal iron absorp-
tion in suckling pups is enhanced to satisfy metabolic needs of
the rapidly growing organism, and is not subjected to negative
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regulation by hepcidin (Darshan et al., 2011). Stabilization of
the IRE-Dmt1 mRNA isoforms by Irps could contribute to the
increased iron absorption capacity before weaning. Surprisingly,
adult mice with enterocyte-specific ablation of both Irps exhib-
ited impaired iron absorption, in spite of the profound induction
of the apical and basolateral iron transporters. This was attributed
to a “mucosal block” imposed by the overexpression of ferritin,
which stores internalized iron and prevents its delivery to the
bloodstream. Therefore, alleviation of the “mucosal block” by
limiting the expression of ferritin emerges as a crucial function of
IRPs, possibly with a major contribution of IRP2, in enterocytes
(Figure 7).
THE IRE/IRP SYSTEM IN SYSTEMIC IRON METABOLISM
Systemic iron metabolism is regulated by hepcidin, a peptide hor-
mone synthesized by liver hepatocytes, which targets ferroportin
in duodenal enterocytes, tissue macrophages and other iron-
exporting cells (Ganz, 2013). The IRE/IRP system appears to
intersect with the hepcidin ferroportin axis. Young Irp1−/−
mice exhibit a marked suppression of hepcidin mRNA, accom-
panied by accumulation of ferroportin in splenic macrophages
(Wilkinson and Pantopoulos, 2013). This response is caused by
the increased erythropoietic activity of these animals due to
induction of Hif2α and Epo, which is an established and potent
inhibitor of hepcidin expression (Ganz, 2013). Irp2−/− mice
were found to have physiological hepcidin mRNA levels, in spite
of hepatic iron overload (Cooperman et al., 2005; Galy et al.,
2005b). However, at the age of 4–6 weeks, these animals showed
a significant induction of hepcidin mRNA expression (Wilkinson
and Pantopoulos, 2013). Conceivably, these seemingly discrepant
findings are related to the antagonistic signals of erythropoi-
etic drive and iron overload, which act as negative or positive
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Ferroportin 
Fe2+ 
Fe2+ 
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IRP 
5’UTR 
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FIGURE 7 | IRPs control dietary iron absorption by limiting ferritin
synthesis in duodenal enterocytes. Regulated expression of ferritin is
essential to prevent a “mucosal block” following iron intake from the
intestinal lumen. In addition, IRPs control the expression of ferroportin and
DMT1 mRNAs, the latter only in the period after birth and before weaning.
Finally, IRP1 controls the expression of HIF2α mRNA, which in turn
transcriptionally induces, among other targets, the iron transporters
ferroportin and DMT1, and the ferrireductase Dcytb. Ferroportin and possibly
also DMT1 are negatively regulated by hepcidin at the level of protein
stability.
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regulators of hepcidin, respectively (Ganz, 2013). These stimuli
do not operate in a strictly hierarchical manner, and their dom-
inance depends on signal strength (Huang et al., 2009). Hepatic
iron overload may be dominant in young animals, and later neu-
tralized by the erythropoietic drive. Nevertheless, 8–10-week-old
liver-specific Irp2−/− mice, which develop hepatic iron over-
load without microcytic anemia, exhibit physiological hepcidin
expression (Ferring-Appel et al., 2009). This may indicate that
Irp2 expression is required for iron-dependent hepcidin induc-
tion in mice older than 4–6 weeks, but the underlying mechanism
is unclear.
The liver is a major site for excessive iron storage within fer-
ritin, but also the central regulator of systemic iron balance via
hepcidin (Meynard et al., 2014). The hepatic iron overload phe-
notype that was observed in mice with global Irp2 disruption per-
sisted in liver-specific Irp2−/− counterparts, which is indicative
of a cell autonomous function (Ferring-Appel et al., 2009). Liver-
specific disruption of both Irp1 and Irp2 resulted in early lethality
within 1–2 weeks after birth due to liver failure (Galy et al., 2010).
This was associated with mitochondrial iron deficiency, as well
as histological and functional defects in this organelle. Thus, the
IRE/IRP system is essential for liver function. Along similar lines,
unregulated overexpression of endogenous Irp2 in liver-specific
Fbxl5−/− mice impaired hepatic and systemic iron homeosta-
sis (Moroishi et al., 2011). The animals developed hepatic iron
overload and steatohepatitis, and exhibited inappropriately low
hepcidin mRNA expression. Moreover, they succumbed after
feeding with an iron-enriched diet due to lethal liver failure.
THE IRE/IRP SYSTEM IN CANCER
Considering that HIF2α may function either as a tumor pro-
moter or suppressor (Keith et al., 2012), the regulation of HIF2α
mRNA translation by IRP1 provides a link between the IRE/IRP
system and cancer biology. Other links were previously pro-
vided by tumor xenograft experiments. Thus, overexpression
of IRP1 or a constitutive IRP1 mutant in human H1299 lung
cancer cells impaired tumor xenograft growth in nude mice
(Chen et al., 2007). Contrary, the overexpression of IRP2 elicited
the opposite phenotype, which required the presence of an
IRP2-specific 73 amino acids domain (Maffettone et al., 2010).
IRE-containingmRNAs were not differentially expressed in IRP1-
or IRP2-overexpressing xenografts, which exhibited distinct gene
expression profiles (Maffettone et al., 2010). These data raise
the possibility for a role of IRPs in modulating cancer growth
independently of their IRE-binding activities, which remains to
be further explored. Nevertheless, IRP2 was recently shown to
be overexpressed in breast cancer cells and to promote tumor
growth by modulating iron metabolism (Wang et al., 2014). This
finding is consistent with reprogramming of iron metabolism in
cancer cells (Torti and Torti, 2013). Notably, in earlier exper-
iments IRP2 was reported to be transcriptionally induced by
the proto-oncogene c-myc and to promote cell transformation
by suppressing ferritin and by regulating cellular iron availabil-
ity (Wu et al., 1999). On the other hand, the tumor suppressor
p53 upregulated ferritin by reducing IRP activities (Zhang et al.,
2008). Development of cancer models with Irp1−/− and Irp2−/−
mice is expected to better define the roles of IRPs in cancer and to
elucidate the molecular basis underlying the association of IRP2
(IREB2) genomic locus with susceptibility to lung cancer (Hansen
et al., 2010; Cho et al., 2012; Fehringer et al., 2012).
CONCLUSIONS
The discovery of the IRE/IRP regulatory system provided a frame-
work to understand the coordinate regulation of cellular iron
uptake via TfR1, and storage within ferritin. Misregulation of L-
ferritin expression due to “loss of function” mutations in the IRE
of its mRNA is clinically relevant and underlies the molecular
basis of the hyperferritinemia-caratact syndrome. The expansion
of IRE-containing mRNAs raised the possibility that IRPs may
control further biochemical pathways. This was firmly established
by the analysis of mousemodels with global or tissue-specific Irp1
and/or Irp2 deficiency. The animal studies highlighted a key role
of the IRE/IRP system in regulation of erythropoiesis, dietary iron
absorption, hepatic iron metabolism and body iron homeostasis
via crosstalk with the hepcidin/ferroportin axis. These findings
may be highly relevant to human medical conditions.
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